Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 5Uterine Cervical Neoplasms 2Uterine Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Phase IB 1Pancreatic Neoplasms 1Neoplasms 1Multiple Myeloma 1Mesonephric Gynecologic Cancer 1Melanoma 1Lymphoma 1Lung Neoplasms 1Low-Grade Serous Ovarian Cancer 1Low Grade Serous Ovarian Cancer 1Hematologic Neoplasms 1Glioma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

defactinib 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase IB × defactinib × Gynecologic × Clear all
NCT07318324 2026-01-06

Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer

M.D. Anderson Cancer Center

Phase 1 Not yet recruiting
31 enrolled
Gynecologic

Phase IB

Data powered by HemOnc (CC BY 4.0) Colophon âš¡